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concentrations, the mean baseline-adjusted QTcF interval 
was −8.4 ms (90 % CI −11.1, −5.7). No patient exhibited 
an absolute QTcF interval of >480 ms. No relationship was 
observed between trastuzumab concentration and baseline-
adjusted QTcF interval. At data cutoff, 84.5 % of patients 
had experienced grade ≥3 adverse events, the most com-
mon of which were hematologic and as expected. Left ven-
tricular ejection fraction remained ≥45 % in all patients 
during the study.
Conclusions The results suggest that trastuzumab had 
no clinically relevant effect on QTcF interval. The safety 
profile of trastuzumab in combination with carboplatin and 
docetaxel was consistent with the known safety profile of 
this combination.
Keywords Carboplatin · Electrocardiogram · Human 
epidermal growth factor receptor 2 · Trastuzumab ·  
QT interval
Introduction
Human epidermal growth factor receptor 2 (HER2) is 
amplified and/or overexpressed in 15–20 % of breast 
cancers [1] and in 10–24 % of gastric/gastroesophageal 
junction cancers [2, 3]. Patients with HER2-positive dis-
ease have a poorer prognosis compared with those with 
HER2-negative disease [4, 5]. The humanized monoclo-
nal antibody trastuzumab (Herceptin®, F. Hoffmann-La 
Roche, Basel, Switzerland) binds to HER2, inhibiting 
ligand-independent HER2 signaling and promoting anti-
body-dependent cell-mediated cytotoxicity of HER2-
positive cancer cells. Trastuzumab improves survival out-
comes when added to chemotherapy for the treatment of 
patients with HER2-positive early breast cancer (EBC) [6], 
Abstract 
Purpose This study evaluated the potential effect of tras-
tuzumab on the electrocardiogram (ECG) QT interval and 
assessed the potential pharmacokinetic interaction between 
trastuzumab and carboplatin. Here, we report the QT and 
safety results.
Methods Patients with metastatic or inoperable HER2-
positive solid tumors received docetaxel and carboplatin 
on Day 1 of each 3-week (q3w) cycle. Trastuzumab was 
administered intravenously, as an accelerated loading dose 
regimen, on Cycle 1, Day 2 and Cycle 1, Day 8, and then 
on Day 1 of each subsequent q3w cycle. ECG assessments 
were performed pre- and posttrastuzumab infusion in the 
first two cycles. Fridericia’s correction was applied to QT 
intervals (QTcF). Baseline-adjusted QTcF intervals (the 
change from baseline) and their 90 % confidence intervals 
(CIs) were calculated.
Results The study enrolled 59 patients. At all time points, 
the 90 % CI upper bound for the mean baseline-adjusted 
QTcF was <10 ms. At steady-state serum trastuzumab 
Electronic supplementary material The online version of this 
article (doi:10.1007/s00280-014-2603-9) contains supplementary 
material, which is available to authorized users.
N. Xu · S. Eppler · B. L. Lum · C. Trudeau (*) 
Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, 
USA
e-mail: trudeau.caroline@gene.com
C. H. Redfern 
Sharp Healthcare, 3075 Health Center Drive, Suite 102,  
San Diego, CA 92123, USA
M. Gordon 
Pinnacle Oncology Hematology, 9055 E. Del Camino, Suite 100, 
Scottsdale, AZ 85258, USA
1252 Cancer Chemother Pharmacol (2014) 74:1251–1260
1 3
HER2-positive metastatic breast cancer (MBC) [7], and 
HER2-positive metastatic gastric or gastroesophageal junc-
tion cancer [8]. Therefore, trastuzumab is approved in the 
USA and EU for use in these settings [9, 10]. In addition 
to the originally approved intravenous formulation of tras-
tuzumab, a subcutaneous formulation of trastuzumab was 
approved in the EU in 2013 for HER2-positive EBC and 
MBC [10].
Trastuzumab therapy has been linked to a low but clini-
cally significant incidence of congestive heart failure, as 
well as decreased left ventricular ejection fraction (LVEF) 
[7, 11]. More broadly, a number of pharmaceutical agents 
have been reported to delay cardiac repolarization, a condi-
tion which favors the development of ventricular arrhyth-
mia. For example, administration of docetaxel has been 
associated with a proarrhythmogenic effect [12]. There-
fore, novel therapeutic agents should be evaluated for their 
potential to prolong the QT interval [as assessed by electro-
cardiogram (ECG)] [13]. Some HER2-targeted agents have 
been linked with QT prolongation. The HER2-targeted 
tyrosine kinase inhibitor lapatinib has been associated with 
prolongation of the corrected QT (QTc) interval from base-
line to postbaseline time points in patients with advanced 
cancer [14]. In an observational study of patients with 
HER2-positive EBC treated with trastuzumab following an 
anthracycline-based regimen, a prolonged QT interval was 
observed compared with patients with HER2-negative EBC 
who were not treated with trastuzumab [15]. In contrast, a 
study of trastuzumab in patients with HER2-positive MBC 
revealed no abnormalities in atrial and ventricular depolari-
zation and repolarization following trastuzumab infusion 
[16]. It should be noted that, due to their large molecular 
weight and high target specificity, monoclonal antibodies 
are not expected to bind to ion channels in the heart in the 
way that small molecules can; therefore, monoclonal anti-
bodies are not expected to have an effect on the QT interval 
[17].
Here, we report results from a phase Ib study with two 
objectives: (1) to evaluate the potential effect of trastu-
zumab on the QTc interval, when combined with carbopl-
atin and docetaxel; (2) to evaluate the potential for a phar-
macokinetic drug–drug interaction between trastuzumab 
and carboplatin in the presence of docetaxel. The pharma-
cokinetic results are reported separately. This manuscript 
focuses on the QTc and safety results from the study.
Methods
Study design and objectives
This was a phase Ib, multicenter, single-arm, open-label 
study of trastuzumab in combination with carboplatin and 
docetaxel (Clinicaltrials.gov registration #NCT00927589). 
The primary ECG objective of the study was to investigate 
the effect of trastuzumab on the duration of the QT interval, 
corrected using Fridericia’s correction (QTcF), as meas-
ured by the change in mean QTcF interval from baseline to 
steady-state trastuzumab.
Patient population
Patients with metastatic or locally advanced, inoperable, 
HER2-positive solid malignancies were eligible for the 
study. HER2-positivity for all tumor types was assessed 
with a testing kit that was FDA-approved for breast can-
cer or, if available, for the patient’s tumor type, including 
immunohistochemistry, fluorescence in situ hybridization, 
or chromogenic in situ hybridization assays, performed by 
a local or reference laboratory. Key exclusion criteria were 
as follows: an Eastern Cooperative Oncology Group per-
formance status of >1, an LVEF of <50 % prior to Cycle 
1, Day 1, a QTcF interval of >450 ms at screening, current 
treatment with medications that alter cardiac conduction 
(e.g., digitalis, β-blockers, or calcium channel blockers), 
ongoing adverse events (AEs) [National Cancer Institute 
Common Terminology Criteria for Adverse Events (NCI-
CTCAE) grade ≥1] related to prior systemic therapy, sur-
gery, or radiotherapy, peripheral sensory neuropathy with 
functional impairment (NCI-CTCAE grade >2) due to fac-
tors other than prior anticancer treatment, a life expectancy 
<12 weeks, trastuzumab therapy within 100 days, or any 
investigational agent within 28 days prior to the start of 
study treatment.
Study treatment
Docetaxel and carboplatin were both administered intrave-
nously on Cycle 1, Day 1, at respective doses of 75 mg/m2 
and target area under the concentration–time curve (AUC) 
of 6 mg/ml/min [18]. Docetaxel and carboplatin continued 
to be administered on Day 1 of each treatment cycle, every 
3 weeks (q3w).
Patients received an unapproved (off-label), acceler-
ated trastuzumab loading dose regimen. Trastuzumab was 
administered intravenously at 6 mg/kg on Cycle 1, Day 2 
and Cycle 1, Day 8, followed by a maintenance dose of 
6 mg/kg on Day 1 of each subsequent q3w treatment cycle 
(Fig. 1). This novel regimen used an accelerated loading 
dose to achieve steady-state trastuzumab concentrations 
earlier (by Cycle 2) and to provide higher serum concentra-
tions, to allow effective assessment of QT effects, in addi-
tion to the pharmacokinetic evaluation. The accelerated 
trastuzumab loading dose regimen had been previously 
studied in a phase I/II trial in which women with HER2-
positive MBC were administered 6 mg/kg of trastuzumab 
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on Days 1, 8, and 15 of the first q3w treatment cycle and 
then on Day 1 of each subsequent q3w cycle [19]. This reg-
imen resulted in trough serum concentrations at the end of 
Cycle 1 (119 mg/l) which exceeded the steady-state trough 
concentrations (50.1 mg/l) achieved with the standard tras-
tuzumab regimen (8 mg/kg loading dose, 6 mg/kg q3w 
maintenance dose). There were no new or unexpected tox-
icities, and the regimen was well tolerated [19].
All study treatment was given until disease progression 
(per investigator assessment), unacceptable toxicity, or 
for up to 12 months after the last patient had enrolled in 
the study, whichever came first. Patients were considered 
to have completed the study once they had received three 
cycles of study treatment or, for patients who continued 
beyond Cycle 3, once they had completed treatment (tras-
tuzumab and/or chemotherapy), at the discretion of the 
investigator. No trastuzumab dose reductions were allowed. 
Dose delays of no more than two cycles were allowed for 
AEs; in the event of dose delays for more than two cycles, 
trastuzumab had to be discontinued. Dose delays and modi-
fications for carboplatin and docetaxel were allowed as per 
their respective prescribing information. The study was 
conducted in accordance with the principles of the Decla-
ration of Helsinki and Good Clinical Practice. The proto-
col was approved by the institutional review board/ethics 
committee of each site and all patients provided written, 
informed consent.
Because of the known risk of QT prolongation from 
5-hydroxytryptamine type 3 (5-HT3) receptor antagonists, 
5-HT3 antiemetics (e.g., granisetron, ondansetron) and 
other QT-prolonging drugs were prohibited on Cycle 1, 
Day 2, Cycle 1, Day 8, and Cycle 2, Day 1, between the 
trastuzumab preinfusion and postinfusion ECG assess-
ments. Antiemetics or other drugs with a risk of QT prolon-
gation and a long half-life (≥4 h) were also prohibited on 
days prior to Cycle 1, Day 2, Cycle 1, Day 8, and Cycle 2, 
Day 1. Because of its influence on QT interval variability, 
nicotine was not allowed in any form from Cycle 1, Day 
1 through Cycle 2, Day 1, inclusive. Alternative antiemetic 
drugs without a known risk of QT prolongation (e.g., 
aprepitant with dexamethasone, or lorazepam) were per-
mitted at the investigator’s discretion and per each drug’s 
prescribing information.
ECG assessments
Triplicate 12-lead ECG readings were taken over a period 
of 2 min at each ECG assessment time point. The average 
of the triplicate ECG readings for each time point was used 
in the analysis. Two ECG assessments were performed 
during the pretreatment period (Study Day −7 to −1) (for 
validation of equipment), and then, ECG assessments were 
performed at the following on-study time points (Fig. 1): 
Cycle 1, Day 2, 30 (±15) min and 15 (±15) min pretras-
tuzumab infusion and 30 (±15) min postinfusion; Cycle 1, 
Day 8 and Cycle 2, Day 1, 15 (±15) min preinfusion and 
30 (±15) min postinfusion.
Serum potassium, magnesium, and calcium levels had 
to be NCI-CTCAE grade ≤1 (as determined by local lab-
oratory testing) before performing ECGs; if electrolyte 
levels were grade >1, patients were to receive electrolyte 
supplements, per standard institutional practice, to reduce 
levels to grade ≤1 prior to perform the ECG. Retesting of 
potassium, magnesium, and calcium levels was performed 
according to standard institutional practice.
A technically qualified central ECG laboratory (Cardi-
ocore, Bethesda, MD, USA) was used to conduct blinded 
ECG readings and interpretation and to provide independ-
ent cardiology services, including consultation with inves-
tigators about patients with prolonged QTc intervals, sup-
plying study sites with uniform, calibrated ECG machines 
capable of digital data transmission, and training technical 
site staff to ensure consistency in ECG acquisitions. All 
ECGs for a patient were performed on the same machine. 
The lead for interval readings was prespecified, and base-
line and on-treatment ECG readings were based on the 
Day 1 Day 2 Day 8 Day 1 Day 1






Day –7 to –1
Fig. 1  Schematic illustration for schedule of study drug administra-
tion and electrocardiogram assessments. ECG electrocardiogram. 
aECG assessments during the pretreatment period were made rela-
tive to the approximate time of future trastuzumab administration. 
On-study ECG assessments—Cycle 1, Day 2: 30 (±15) and 15 (±15) 
min preinfusion, 30 (±15) min postinfusion; Cycle 1, Day 8: 15 
(±15) min preinfusion, 30 (±15) min postinfusion; Cycle 2, Day 1: 
15 (±15) min preinfusion, 30 (±15) min postinfusion
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same lead. ECG readings were performed before collecting 
any corresponding pharmacokinetic samples. ECG readers 
were blinded to treatment details, time, and day identifiers. 
All ECG readings from a particular patient were reviewed 
by a single reader on 1 day.
ECG analysis
The ECG analysis was performed in the ECG-evaluable 
patient population, which consisted of all patients who: (1) 
had received any trastuzumab doses; (2) had at least one 
interpretable baseline ECG assessment; (3) had at least one 
interpretable ECG assessment performed at steady-state 
trastuzumab concentration; and (4) had no infusion reac-
tion requiring treatment.
The average of the two ECG assessments performed 
prior to the first trastuzumab infusion (on Cycle 1, Day 2) 
was used as the baseline ECG measurement. The off-label, 
accelerated trastuzumab loading dose regimen in this study 
was used to achieve earlier steady-state trastuzumab con-
centrations, such that ECG assessments on Cycle 1, Day 
8 and Cycle 2, Day 1 were made at steady-state trastu-
zumab concentrations; thus, the average of Cycle 1, Day 
8 and Cycle 2, Day 1 postinfusion ECG assessments was 
used as the ECG measurement at steady-state trastuzumab 
concentrations. Since QT intervals are inversely correlated 
with heart rate, QT was corrected using Fridericia’s correc-
tion (QTcF = QT/RR0.33). In addition, secondary analyses 
were performed using Bazett’s correction (QTcB = QT/
RR0.5). Ninety percent two-sided confidence intervals (CIs) 
for QTcF and QTcB intervals were calculated, in line with 
International Conference on Harmonization (ICH) E14 
guidance [13]; an upper bound of the 90 % two-sided CI 
of ≥20 ms was considered the threshold for clinical con-
cern [20]. The proportions of patients at each time point 
within absolute QTc interval categories, as defined by ICH 
E14 guidance, were summarized. Secondary ECG param-
eters (heart rate, PR, RR, and QRS intervals) were also 
investigated.
All study treatment administration, ECG readings, and 
pharmacokinetic sampling were to be performed at approx-
imately the same time of day and >1 h postprandial, to 
minimize variations due to circadian rhythms or eating, and 
to ensure that baseline and postdose ECGs were time win-
dow matched.
An exploratory analysis was carried out to assess any 
potential correlation between serum trastuzumab concen-
tration and the change from baseline in QTcF interval. Indi-
vidual baseline-adjusted QTcF values were plotted against 
serum trastuzumab concentrations from corresponding 
pharmacokinetic samples. A least-squares model (with no 
stratification for patient or cycle) was fit to the data, and the 
gradient of the line of linear fit was derived.
Safety assessments
After initiation of study medications, all AEs and serious 
AEs, regardless of causality, were reported until the study 
completion/early termination visit (28–42 days after the 
last dose of study treatment). After this period, investiga-
tors only reported serious AEs that were considered to be 
related to study treatment. AEs were elicited and recorded 
at each study visit. All AEs were summarized by System 
Organ Class, preferred term, and NCI-CTCAE version 3.0 
severity grade. LVEF was monitored by echocardiography 
and/or multiple-gated acquisition every 12 weeks, or more 
often if clinically indicated.
Results
Between July 6, 2009 and April 11, 2012, 59 patients from 
14 US sites enrolled in the study. At the clinical cutoff date 
of February 20, 2013, 43 patients (72.9 %) had received 
≥3 cycles of study treatment, six patients (10.2 %) had dis-
continued after treatment at Cycle 3 but before completing 
the cycle, 37 patients (62.7 %) had discontinued after com-
pleting Cycle 3, and 16 patients (27.1 %) had discontinued 
before Cycle 3 (including one patient who received no study 
treatment). Since one patient received no study treatment, 
there were 58 safety-evaluable patients. One patient with-
drew on Cycle 1, Day 2, prior to receiving trastuzumab, and 
four patients had missing postinfusion ECG data. Therefore, 
the ECG-evaluable population consisted of 53 patients.
An overview of patient demographics and baseline dis-
ease characteristics is provided in Supplementary Table 1. 
Patients had a median age of 61 and an Eastern Coopera-
tive Oncology Group performance status of 1 (50.8 %) or 0 
(49.2 %). Nine patients (15.3 %) had received prior anthra-
cycline-based chemotherapy.
5-HT3 receptor antagonist antiemetics and a number 
of other drugs are known to prolong the QT/QTc interval. 
Despite these drugs being prohibited in this study, patients 
who received restricted concomitant medications (protocol 
violators) were not excluded from the ECG-evaluable pop-
ulation. Prior to ECG data collection, 38 of the 53 ECG-
evaluable patients (71.7 %) received at least one restricted 
concomitant medication with a known risk of QT prolon-
gation. The most frequently reported restricted concomitant 
medications were diphenhydramine [29 patients (54.7 %)], 
ondansetron hydrochloride [14 (26.4 %)], and prochlorp-
erazine [12 (22.6 %)].
QTc results
QT interval duration was negatively correlated with heart 
rate and positively correlated with RR interval duration, as 
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shown in Supplementary Fig. S1. QT intervals were cor-
rected using Fridericia’s (QTcF) and Bazett’s (QTcB) 
methods. Using Fridericia’s correction, the effects of heart 
rate and RR interval on QT interval were reduced, as shown 
by plotting individual average QTcF intervals against time-
matched heart rates and RR intervals (Supplementary Fig. 
S1). This produced linear-fitted lines with small gradients, 
thus demonstrating no apparent relationship between QTcF 
interval and heart rate or RR interval, and thereby confirm-
ing the suitability of the QTcF correction method. In con-
trast, more variability was observed when using Bazett’s 
correction, with QTcB intervals overcorrected at higher 
heart rates and undercorrected at lower heart rates (Supple-
mentary Fig. S1).
The mean baseline-adjusted (i.e., the change from base-
line) average QTcF interval (90 % two-sided CI) at each 
ECG assessment time point is shown in Fig. 2. For all 
time points, the upper bound of the 90 % two-sided CI was 
<10 ms. At 30 min postinfusion on Cycle 1, Day 2, the mean 
baseline-adjusted average QTcF interval was increased by 
3.5 ms. At all other time points, the mean baseline-adjusted 
average QTcF intervals were reduced, with the lowest val-
ues occurring at Cycle 2, Day 1 pre- and postinfusion time 
points (−15.6 and −13.4 ms, respectively). Box plots of 
baseline-adjusted average QTcF intervals are shown in Sup-
plementary Fig. S2. The majority of ECG readings were 
collected within the protocol-defined time window.
At steady-state trastuzumab concentrations (the average 
of postinfusion ECG assessments on Cycle 1, Day 8 and 
Cycle 2, Day 1), the mean baseline-adjusted QTcF interval 
was −8.4 ms (90 % CI −11.1, −5.7). Similarly, the mean 
baseline-adjusted QTcB interval at trastuzumab steady-
state was −5.9 ms (90 % CI −9.2, −2.6).
The proportions of patients within absolute QTc inter-
val categories, as defined by ICH E14 guidance, at each 
time point are presented in Table 1. No patient exhibited an 
absolute QTcF interval of >480 ms. Five patients at Cycle 
1, Day 2 postinfusion, one patient at Cycle 1, Day 8 prein-
fusion, and two patients at Cycle 1, Day 8 postinfusion had 
absolute QTcF intervals between >450 and ≤480 ms. Com-
pared with the QTcF interval, more patients had an absolute 
QTcB interval of >450 ms. At Cycle 1, Day 2 postinfusion, 
one patient had an absolute QTcB interval of >500 ms and 
two patients had absolute QTcB intervals between >480 
and ≤500 ms. At Cycle 1, Day 8, two patients had abso-
lute QTcB intervals between >480 and ≤500 ms (one pre-
infusion and one postinfusion). No patient had a baseline-
adjusted QTcF interval of >30 ms, while one patient had 
a baseline-adjusted QTcB interval of >30 to ≤60 ms (at 
Cycle 1, Day 8, 30 min postinfusion). These results reflect 
the different correction factor used with Bazett’s method, 
which is generally acknowledged as a less ideal correction 
compared with Fridericia’s method.
The mean baseline-adjusted average PR interval 
increased over time to a maximum of 13.7 ms at the Cycle 
2, Day 1, 30 min postinfusion time point. Overall, however, 
baseline-adjusted secondary ECG parameters showed no 
obvious trends that would suggest a clinical risk of cardiac 
dysrhythmia (Table 2). One patient’s PR interval duration 
was increased from baseline by ≥25 % and to an absolute 
value >200 ms at three time points; however, this patient 
experienced no cardiac or other relevant AEs; no patient 
had a QRS interval duration increased from baseline by 
≥25 %. No patient had significant or nonsignificant abnor-
mal U-wave changes from baseline and no patient had 
significant abnormal T-wave changes from baseline; the 
Fig. 2  Mean baseline-adjusted 
QTcF interval (90 % two-sided 
confidence interval) by nominal 
electrocardiogram time point. 
CI confidence interval, QTcF 
QT interval corrected using 
Fridericia’s correction
Cycle 1, Day 2
post-infusion
Cycle 1, Day 8
pre-infusion
Cycle 1, Day 8
post-infusion
Cycle 2, Day 1
pre-infusion
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Table 1  QTc intervals by 
nominal electrocardiogram 
time point based on ICH E14 
guidance
ECG electrocardiogram, ICH 
international conference on 
harmonization, QTcB QT 
interval corrected using Bazett’s 
correction, QTcF QT interval 
corrected using Fridericia’s 
correction
a
 Number of patients with data 
available at that time point
ECG measure ECG time point na Patients, n (%)
≤450 ms >450–≤480 ms >480–≤500 ms >500 ms
QTcF Cycle 1, Day 2
 30 min postinfusion 49 44 (89.8) 5 (10.2) 0 0
Cycle 1, Day 8
 15 min preinfusion 50 49 (98.0) 1 (2.0) 0 0
 30 min postinfusion 50 48 (96.0) 2 (4.0) 0 0
Cycle 2, Day 1
 15 min preinfusion 48 48 (100) 0 0 0
 30 min postinfusion 48 48 (100) 0 0 0
QTcB Cycle 1, Day 2
 30 min post-infusion 49 36 (73.5) 10 (20.4) 2 (4.1) 1 (2.0)
Cycle 1, Day 8
 15 min preinfusion 50 41 (82.0) 8 (16.0) 1 (2.0) 0
 30 min postinfusion 50 39 (78.0) 10 (20.0) 1 (2.0) 0
Cycle 2, Day 1
 15 min preinfusion 48 43 (89.6) 5 (10.4) 0 0
 30 min postinfusion 48 43 (89.6) 5 (10.4) 0 0
Table 2  Summary statistics for baseline-adjusted secondary electrocardiogram measures
n is the number of patients with data available at that time point
bpm beats per minute, ECG electrocardiogram, QTcB QT interval corrected using Bazett’s correction, QTcF QT interval corrected using Frideri-
cia’s correction, SD standard deviation
ECG time point QTcF (ms) QTcB (ms) QT (ms) PR (ms) QRS (ms) RR (ms) Heart rate (bpm)
Cycle 1, Day 2
 30 min postinfusion (n = 49)
  Mean (SD) 3.5 (11.8) 3.9 (9.7) 2.9 (24.5) −0.1 (9.4) −0.1 (4.0) 0.3 (102.9) 0.5 (9.9)
  Median 3.8 3.7 2.3 0.5 −0.7 0.0 0.2
  Range −30.8 to 28.2 −18.5 to 23.2 −67.3 to 50.3 −25.7 to 37.8 −10.3 to 9.0 −246.0 to 219.8 −16.5 to 31.7
Cycle 1, Day 8
 15 min preinfusion (n = 50)
  Mean (SD) −9.3 (12.1) −0.8 (14.5) −24.3 (29.0) 1.4 (14.6) −1.8 (5.5) −99.7 (144.1) 9.6 (14.9)
  Median −6.3 1.0 −19.5 −1.5 −1.5 −94.0 8.1
  Range −47.3 to 10.3 −41.3 to 24.8 −103.0 to 26.3 −34.0 to 61.8 −18.8 to 10.8 −524.0 to 167.5 −18.2 to 40.8
Cycle 1, Day 8
 30 min postinfusion (n = 50)
  Mean (SD) −4.3 (12.0) 1.4 (14.6) −14.7 (27.5) 4.2 (11.8) −1.8 (5.8) −69.1 (137.8) 6.2 (13.7)
  Median −4.6 1.3 −8.5 2.3 −1.3 −55.2 4.2
  Range −28.2 to 24.7 −28.0 to 31.7 −96.7 to 29.7 −15.3 to 45.5 −20.8 to 11.3 −522.0 to 198.2 −20.8 to 38.8
Cycle 2, Day 1
 15 min preinfusion (n = 48)
  Mean (SD) −15.6 (13.3) −13.2 (16.6) −20.3 (27.0) 9.7 (13.1) −0.5 (5.0) −39.9 (139.3) 3.1 (12.7)
  Median −15.9 −14.8 −17.7 7.4 0.3 −30.8 2.8
  Range −43.8 to 7.8 −53.5 to 21.0 −79.3 to 40.3 −14.8 to 70.8 −16.0 to 7.8 −304.0 to 271.7 −22.3 to 28.0
Cycle 2, Day 1
 30 min postinfusion (n = 48)
  Mean (SD) −13.4 (14.6) −14.2 (18.6) −12.6 (26.1) 13.7 (16.1) −0.3 (6.0) −3.4 (136.7) −0.7 (12.1)
  Median −12.2 −12.3 −12.1 13.3 0.4 −13.3 0.8
  Range −45.0 to 11.2 −59.8 to 28.3 −76.3 to 38.7 −12.8 to 92.5 −22.0 to 10.3 −283.0 to 368.0 −30.8 to 23.7
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maximum number of patients with nonsignificant abnormal 
T-wave changes from baseline at any time point during the 
study was six (at Cycle 1, Day 8, 30 min postinfusion).
An exploratory analysis was performed to assess 
whether any relationship existed between trastuzumab 
concentration and QTc interval. The Cycle 1, Day 2 pre-
infusion mean (95 % CI) trastuzumab concentration was 
0.2 (0.2, 0.2) μg/ml; the mean Cycle 1, Day 8 and Cycle 
2, Day 1 postinfusion concentrations were 186.4 (172.2, 
201.7) and 179.1 (166.8, 192.4) μg/ml, respectively. The 
concentration–QTc dataset consisted of 297 ECG assess-
ments with parallel trastuzumab concentration measure-
ments from 53 patients, and contained data collected at 
trough and peak steady-state trastuzumab concentrations. A 
linear least-squares fit of trastuzumab concentration versus 
baseline-adjusted QTcF interval produced a slope of linear 
fit with a small gradient, close to 0 (0.0009), indicating no 
apparent relationship between trastuzumab concentration 
and baseline-adjusted QTcF interval (Fig. 3).
Safety results
At data cutoff, the median duration of follow-up on study 
(the time from enrollment to the last on-study assessment) 
was 4.4 months (range 0.0–37.7 months). Patients had 
received a median of seven (range 1–52), four (range 1–24), 
and four (range 1–51) doses of trastuzumab, carboplatin, 
and docetaxel, respectively, and the median duration of 
trastuzumab treatment was 15 weeks (range 0–163 weeks). 
Fifty-seven out of 58 safety-evaluable patients had received 
at least one dose of trastuzumab.
A total of 57 out of 58 safety-evaluable patients 
(98.3 %) experienced AEs of any grade, and 49 patients 
(84.5 %) had experienced grade ≥3 AEs, the most com-
mon of which (in ≥4 patients) are shown in Table 3. 
Serious AEs were reported by 26 patients (44.8 %). Six 
patients (10.3 %) discontinued trastuzumab due to AEs, 
none of which were cardiac-related; two of these patients 
withdrew prematurely, before completing Cycle 3. Two 
patients (3.4 %) died during the study. One death was due 
to an AE of hemorrhagic stroke (considered by the inves-
tigator to be unrelated to trastuzumab), and the other was 
due to disease progression.
Eight patients experienced cardiac AEs. The mean LVEF 
at baseline was 64.0 % [standard deviation (SD): 8.6 %], 
and the mean lowest LVEF value postbaseline was 59.5 % 
(SD: 6.6 %). Forty-four patients (93.6 %) had LVEF val-
ues of ≥50 % at all postbaseline time points; no postbase-
line values of <45 % were observed during the study. Two 
patients experienced grade 2 left ventricular dysfunction. 
One of these events, considered by the investigator to be 
related to trastuzumab, resolved after 21 days and had no 
associated ECG changes. The other left ventricular dys-
function event, considered to be unrelated to trastuzumab, 
was ongoing at the end of the study. The patient had a his-
tory of left bundle branch block and had experienced an 
AE of prolonged QT interval several weeks prior to the 
left ventricular dysfunction event. This patient’s prolonged 
QT interval was an isolated grade 1 AE. Prior to this event, 
the patient experienced grade 2 hypocalcemia but did not 
receive the protocol-required calcium supplementation (and 
was therefore a protocol violator).



















Serum trastuzumab concentration (µg/ml)
Fig. 3  Relationship between baseline-adjusted QTcF interval and 
serum trastuzumab concentration. QTcF QT interval corrected using 
Fridericia’s correction. A least-squares model (with no stratification 
for patient or cycle) was fit to the data, with line of linear fit (solid 
line, slope = 0.0009, p = 0.926) and smoothed curve (dotted line, fit-
ted using the S-Plus LOESS function)
Table 3  Overview of adverse events
Patients, n (%)
Any adverse event 57 (98.3)
Any serious adverse event 26 (44.8)
Any grade ≥3 adverse event 49 (84.5)
Grade ≥3 adverse events in ≥4 patients
 Neutrophil count decreased 33 (56.9)
 White blood cell count decreased 13 (22.4)
 Hemoglobin decreased 9 (15.5)
 Platelet count decreased 9 (15.5)
 Dehydration 5 (8.6)
 Diarrhea 5 (8.6)
 Fatigue 5 (8.6)
 Febrile neutropenia 5 (8.6)
 Hyperglycemia 4 (6.9)
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The results of this study suggest that trastuzumab had no 
clinically relevant effect on the duration of the QTcF or 
QTcB intervals in patients with HER2-positive metastatic 
or locally advanced, inoperable solid tumors. At the first 
postinfusion ECG assessment, the mean QTcF interval was 
increased slightly from baseline; at all subsequent time 
points, mean QTcF intervals were reduced from baseline. 
No patients had absolute QTcF interval durations that were 
within the range of clinical concern, i.e., there were no 
absolute values of >480 ms or increases from baseline of 
>30 ms. Additional ECG parameters (heart rate, QT, PR, 
RR, and QRS intervals) were not altered. Importantly, sus-
tained QT interval prolongation did not occur even though 
a substantial proportion of patients received at least one 
restricted concomitant medication with a known risk of 
prolonging the QT interval. Furthermore, there was no rela-
tionship observed between serum trastuzumab concentra-
tion and change from baseline in QTcF interval duration. 
It should be noted that this study employed an unapproved 
(off-label), accelerated trastuzumab loading dose regimen 
to achieve steady-state serum trastuzumab concentrations 
early, in order to test more rigorously for potential effects 
on QT interval.
Increased rates of cardiac dysfunction were an unex-
pected observation during the clinical development of tras-
tuzumab, influencing the design of subsequent trials, in 
which LVEF was monitored more frequently and stricter 
cardiac eligibility criteria were applied [7, 21, 22]. Tras-
tuzumab-related cardiac dysfunction, which is dose-inde-
pendent and reversible in most patients [22, 23], is believed 
to be related to cardiomyocyte HER2 expression. HER2 is 
thought to play a critical role in cardiac development, car-
diomyocyte repair and survival, and in modulating myo-
cardial stress responses in the adult heart [24–28]. Despite 
these insights, the potential arrhythmogenic effect of trastu-
zumab required further exploration.
Previous reports evaluating QT interval during trastu-
zumab-based therapy have been conflicting. An observa-
tional study reported long-term treatment with trastuzumab 
to be associated with significantly prolonged QT interval. 
However, this study compared patients with HER2-positive 
and HER2-negative EBC. Furthermore, the results were 
confounded by the use of anthracycline-based chemo-
therapy, which is known to affect cardiac function [15]. In 
another study, no acute effects on cardiac repolarization 
were seen following trastuzumab infusion [16]. Data from 
clinical studies of two other HER2-targeted humanized 
monoclonal antibodies, trastuzumab emtansine (Kadcyla®, 
F. Hoffmann-La Roche, Basel, Switzerland) and pertu-
zumab (PERJETA®, F. Hoffmann-La Roche, Basel, Swit-
zerland), have also demonstrated no effect on QT interval 
[29, 30]. The lack of an observed effect of trastuzumab on 
QT interval is consistent with the molecular mechanism 
through which pharmaceutical agents are thought to affect 
cardiac repolarization [17]. Small molecules can bind to 
human ether-à-go-go-related gene (hERG) ion channels, 
disrupting ionic current. In contrast, monoclonal antibod-
ies, such as trastuzumab, have a relatively large molecu-
lar size and high target specificity and are therefore not 
expected to access the drug-binding site of hERG channels.
Evaluation of the potential effect of trastuzumab on QT 
interval using a thorough QT study, as defined by ICH E14 
guidance [13], was not feasible in the context of our study, 
as with other oncology studies [31]. Trastuzumab, in combi-
nation with carboplatin and docetaxel, could not be admin-
istered to healthy volunteers due to the potential for toxic-
ity, and supratherapeutic doses of trastuzumab could not be 
administered to patients, although it should be noted that the 
dosing regimen used in our study is the highest dose that has 
ever previously been administered to patients. Furthermore, 
a crossover study involving a washout period, and placebo 
treatment was not deemed ethical in patients with cancer. 
Despite these considerations, our study was designed to rigor-
ously investigate QT interval; it employed a central ECG lab-
oratory, well-calibrated ECG machines, blinded, independent 
reviewers, and time window-matched ECG assessments.
In this study, trastuzumab in combination with carbopl-
atin and docetaxel had an acceptable safety profile which 
was comparable to the known safety profile of the tras-
tuzumab, carboplatin, and docetaxel regimen in patients 
with HER2-positive EBC [32]. No QT prolongation was 
observed in patients with HER2-positive metastatic or 
locally advanced solid tumors when trastuzumab was 
administered as an accelerated loading dose regimen, in 
combination with carboplatin and docetaxel. Based on the 
results of this study, it is unlikely that trastuzumab admin-
istered via the approved dosing regimen would prolong 
the duration of the QT interval in clinical practice. Further 
exploration may be required to confirm this.
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